Welcome to our dedicated page for Denali Capital Acquisition news (Ticker: DECA), a resource for investors and traders seeking the latest updates and insights on Denali Capital Acquisition stock.
Denali Capital Acquisition Corp. is a blank-check company whose news centers on SPAC deadline extensions, trust-account deposits and shareholder actions tied to its effort to complete an initial business combination. Updates commonly cover one-month extension funding, convertible promissory note financing, redemption-related trust mechanics, extraordinary general meeting adjournments and votes on amendments to its governing documents.
Longevity Biomedical, a biopharmaceutical firm, has entered into a definitive business combination agreement with Denali Capital Acquisition Corp (NASDAQ: DECA). This partnership aims to consolidate and enhance the development of longevity-related products and services for the aging population, with a transaction value approximating $236.2 million. Following the merger, the combined entity will trade on Nasdaq under the symbol 'LBIO'. The transaction is projected to provide a minimum cash balance of $30 million, supporting clinical milestones for its therapeutic pipeline, including LBI-201 for ischemic stroke and LBI-101 for soft tissue repair.